AEterna Zentaris (AEZS)
News
| May 22 | $FB sucks, most of my friends already deleted their accounts. $KERX and $AEZS will continue to climb hopefully. by nd4spd30 |
| May 18 | $aezs couldnt reverse it yesterday?!?!?!? Fine... by HighRiskBuyer |
| May 18 | $AEZS Mentioned more than normal on StockTwits - Currently at 2 x average daily social activity by TradeIdeasQuant |
| May 18 | RT @AvantNoir: @HighRiskBuyer I bought $AEZS at 0.48-this is ridiculous today. I added more, not going to look again today. Whole sector red by HighRiskBuyer |
| May 18 | @HighRiskBuyer I bought $AEZS at 0.48, didn't expect the second drop so early.. or rather the 1 day late reaction from investors by AvantNoir |
| May 18 | $AEZS here we go again, same scenario as a few years ago, not in compliance with nasdaq. This stock always promised but never delivered :o( by boardroom |
| May 18 | Looking for some nice green for $clsn and $chtp today, $aezs next week. Anyone want a hit? by HighRiskBuyer |
| May 18 | $AEZS they got a freebie on that opening. Holding. Buy alerts were sent out this morning. Volume up already. by HighRiskBuyer |
| May 17 | $aezs price should actually bounce back a bit tmrw, this really is near or on the bottom of the barrel. by HighRiskBuyer |
| May 17 | $aezs now seriously, a couple good notes. Current pps is pennies above cash/book value. Short interest decreased 13-8% http://stks.co/3sxP by HighRiskBuyer |
| May 16 | Aeterna Zentaris (AEZS) Gets Minimum Bid Notification from Nasdaq Street Insider |
| May 16 | Aeterna Zentaris Receives Notification from NASDAQ Relating to Minimum Bid Price Benzinga |
| May 07 | Aeterna (AEZS), Keryx (KERX) Terminate Perifosine License Agreement in North America Street Insider |
| May 07 | Aeterna Zentaris Regains North American Rights for Perifosine from Keryx Benzinga |
| May 01 | 1 Biotech Back From the Dead Fool |
Profile
Exchange: NASDAQGM Sector: Healthcare Industry: Biotechnology
Ãterna Zentaris Inc. is a Quebec, Canada-based biopharmaceutical company focused in oncology and endocrine therapy. It has over 100 employees in Canada, USA and Germany. The company is based in Canada, the development and research site ist based in Germany. AEterna Zentaris recently received FDA fast track and orphan status for Perifosine, a drug with multiple niche applications in cancer treatment.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). AEterna Zentaris is down 79.12% over the last year vs S&P 500 Total Return up 0.94%, ARIAD Pharmaceuticals up 90.36%, and Discovery Laboratories up 7.61%.
- AEZS Total Returns
- ^SPXTR Total Returns
- ARIA Total Returns
- DSCO Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these AEZS related companies
Pro Strategies Featuring AEZS
Did AEterna Zentaris make it into our Pro Portfolio Strategies?
AEZS Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other AEZS Resources
- Wiki Page
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AEZS | 0.4699 | -0.01 | -2.10% | 50.77M |
| AETI | 4.52 | +0.04 | +0.89% | 35.08M |
| AER | 11.36 | -0.01 | -0.09% | 1.590B |
| AEP | 37.79 | -0.27 | -0.71% | 18.42B |
| AEM | 39.20 | +2.03 | +5.46% | 6.353B |
